Jacek Olczak 5.0 2 ideas

"By 2030, we should have a total of the revenues coming from this product [smoke-free]." Additionally, "IQOS today's revenue is larger than Marlboro" and Zyn shipments are predicted to hit 1 billion in 2026. PMI has successfully executed a "self-disruption" strategy. By acquiring Swedish Match (Zyn) and developing IQOS, they have immunized themselves against the secular decline of smoking. They are capturing a new demographic (white-collar workers) who would never smoke cigarettes but will use discreet pouches. The construction of the Colorado facility indicates massive demand and a move to secure US market share against competitors like Altria. Long PM as the clear winner in the "Nicotine 2.0" transition, offering growth (Zyn) and stability (legacy pricing power) with a valuation that may re-rate higher as it becomes less of a "sin stock" and more of a consumer packaged goods (CPG) play. Regulatory crackdown on flavored pouches (similar to vaping bans); long-term health studies revealing cardiovascular risks associated with high-concentration nicotine pouches.

Olczak states that 40% of Philip Morris International's revenue is now "smoke-free" (IQOS and Zyn). He projects Zyn shipments to more than double from 421 million cans in 2023 to over 1 billion in 2026. The market historically discounts tobacco for terminal decline in combustibles. However, PM is successfully transitioning to a growth multiple business (Oral Nicotine/Heat-not-Burn). If Zyn volumes double, revenue quality improves, warranting a re-rating from "value trap" to "growth staple." Long PM as the clear winner in the nicotine transition, specifically for its ownership of Zyn (US growth engine) and IQOS (International scale). Regulatory crackdowns on flavored pouches; potential long-term health studies linking pouches to cardiovascular issues.